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Abstract Acidic fibroblast growth factor (aFGF) is a 
member of the structurally related heparin-binding 
growth factor family. The best studied members of this 
family are aFGF and basic FGF (bFGF), which are po- 
tent mitogens and differentiation factors for mesoderm- 
derived cells, including fibroblasts. This study was de- 
signed to verify the immunohistochemical expression of 
aFGF in normal human endocrine cells of the gut and in 
related endocrine turnouts. We examined normal gastro- 
intestinal mucosa from seven different subjects and 41 
gut endocrine tumours from different sites, including 
stomach, duodenum, and small and large intestine, using 
an aFGF polyclonal antibody with no cross-reactivity for 
bFGF. We localized aFGF in a fraction of serotonin-pro- 
ducing enterochromaffin (EC) cells of the normal gut, 
while it was absent in gastrin (G), CCK, secretin (S), so- 
matostatin (D) and glicentin (L) cells, aFGF immunore- 
activity was also expressed in serotonin producing EC 
cell turnouts, but not in other functional types of gut en- 
docrine neoplasms investigated, including gastric ECL 
cell, duodenal somatostatin a d gastrin cell, and rectal L 
cell tumours. A positive correlation was found between 
expression of aFGF and the amount of turnout fibrous 
stroma, suggesting that aFGF may be involved in prolif- 
eration and activity of stromal fibroblasts. 
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Introduction 
Acidic fibroblast growth factor (aFGF or FGF-1) belongs 
to a large family of homologous polypeptide growth fac- 
tors that have an affinity for heparin and glycosamino- 
glycans [10, 29]. This family also includes basic fibro- 
blast growth factor (bFGF or FGF-2), int-2 (FGF-3), Ka- 
posi sarcoma FGF (FGF-4), FGF-5, FGF-6, and kerati- 
nocyte growth factor (FGF-7) [10, 24, 29]. aFGF is a sin- 
gle-chain anionic polypetide with a molecular weight of 
about 18,000, coded by a gene positioned on human 
chromosome 5 between bands 5q31.3 and 5q33.2 [38]. It 
was found to be chemotactic for fibroblasts, and able to 
promote angiogenesis and proliferation of fibroblasts and 
other mesoderm-derived c lls, including heart myocytes 
[3, 10, 17, 19, 20, 22, 24, 26, 29]. Its biological proper- 
ties, including the ability to stimulate angiogenesis and 
formation of granulation tissue, suggest apossible role in 
physiological wound healing [19, 29]. In addition, aFGF 
has been proved to be a neurotrophic factor, which regu- 
lates neuronal cell differentiation and survival both in 
vitro and in vivo [25, 48, 49]. Although aFGF does not 
seem to have a direct role as an autocrine factor in tu- 
mour progression, it could act as a paracrine factor stim- 
ulating angiogenesis necessary for neoplastic cell growth 
[29]. However, the precise role and function of aFGF in 
normal and neoplastic tissues is not known. 
aFGF is widely distributed in human and other mam- 
malian tissues. It was primarly found in neural tissue, in- 
cluding brain [31, 33], hypothalamus [32] and retina [14, 
16], and has been extracted or immunohistochemically 
detected in bone matrix [27], kidney [23], uterus [9], 
pancreas [21], parathyroid [45], breast [4] and salivary 
glands [40]. Information on aFGF localization in endo- 
crine cells of the human gut is lacking. 
Endocrine turnouts of the gastrointestinal tract (car- 
cinoids) are slow-growing neoplasms, which often show 
striking fibroblastic reaction in the turnout stroma, pro- 
liferation of smooth muscle within the turnouts, pro- 
nounced serosal fibrosis, obliterative lastic sclerosis of 
mesenteric blood vessels and, sometimes, fibroelastosis 
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of the inside surfaces of the cardiac hambers and valvu- 
lar leaflets, mainly of the right side, resulting in so-called 
carcinoid heart disease. In particular, these features are 
typical of midgut serotonin-producing enterochromaffin 
(EC) cell tumours (argentaffin carcinoids). Previous 
studies have considered the possible role of TGFo~, 
TGF~, PDGF, insulin-like growth factor-I and bFGF in 
the stimulation of stromal fibrosis and in neoplastic 
growth regulation of gastrointestinal endocrine tumours 
[1, 5, 7, 12, 13, 42]. 
Studies on localization of aFGF in endocrine neo- 
plasms and related normal endocrine cells of the human 
gut have not been previously reported. We performed im- 
munohistochemical investigations to characterize aFGF 
production by normal and neoplastic endocrine cells of 
the gut using specific antibodies for aFGF. We observed 
aFGF expression i  serotonin-producing EC cells of the 
normal gastrointestinal mucosa nd in intestinal EC cell 
tumours (argentaffin carcinoids). 
Materials and methods 
We studied samples of normal human stomach and small and large 
bowel collected at surgery from seven different subjects (four 
males, three females). We also examined 41 endocrine tumours of 
the gastrointestinal tract (7 ECL cell tumours and 2 poorly differ- 
entiated neuroendocrine carcinomas of the stomach, 1 gastrin cell 
tumour and 1 somatostatin cell tumour of duodenum, 1 jejnneal 
well differentiated endocrine carcinoma, 9 ileal, 8 appendiceal, 4 
right colon and 2 rectal serotonin-producing EC cell tumours, 1 
appendiceal and 5 rectal glicentin- and PP-producing L cell tu- 
Table 1 Summary of clinico-pathological data and immunohisto- 
chemical staining of 41 endocrine tumours of the gastrointestinal 
tract (he not evaluated, aFGF acidic fibroblast growth factor, Glic 
glicentin-glucagon, 5HT serotonin, 
SubP substance P, Sore somatostatin) 
PP pancreatic polypeptide, 
No. Sex Age Site Type Size Fibrous 
(cm) stroma b 
Metastases Markers (% of positive cells) 
Sore PP Glic 5HT SubP aFGF 
1 F 46 Stomach Type 1 [44] 1.5 + 
2 F 65 Stomach Type 1 ne ne 
3 F 90 Stomach Type 1 ne ne 
4 M 76 Stomach Type 1 2 ++ 
5 M 43 Stomach Type3 [44] 2 + 
6 M 26 Stomach Type3 2 + 
7 M 44 Stomach Type 3 2 ++ 
8 M 68 Stomach NEC [44] 3 + 
9 M 52 Stomach NEC 5 + 
10 F 52 Duodenum D-cell 1.5 + 
l 1 a F 42 Duodenum G-cell 1 ++ 
12 F 38 jejunum Undefined-cell 1.2 + 
13 F 67 Ileum EC cell 2 ++ 
14 M 52 Ileum EC cell 2 +++ 
15 M ne Ileum EC cell 2.5 ++ 
16 F 46 Ileum EC cell 1.5 ++ 
17 M 59 Ileum EC cell 2.5 ++ 
18 M 58 Ileum EC cell 2.5 ++ 
19 M 39 Ileum EC cell 3 +++ 
20 F 75 Ileum EC cell 1.5 +++ 
21 F 69 Ileum EC cell 2 ++ 
22 M 53 Appendix EC cell 2.5 +++ 
23 M 25 Appendix EC cell 0.5 ++ 
24 F 95 Appendix EC cell 2 ++ 
25 F 14 Appendix EC cell 0.6 +++ 
26 F 17 Appendix EC cell 0.5 ++ 
27 F 24 Appendix EC cell 0.2 +++ 
28 M 27 Appendix EC cell 0.5 +++ 
29 F 21 Appendix EC cell 0.3 + 
30 F 24 Appendix L cell 1.5 +++ 
31 F ne Right colon EC cell ne ne 
32 ne ne Right colon EC cell ne +++ 
33 F 50 Right colon EC cell ne ++ 
34 M 46 Right colon EC cell 8 ++ 
35 F 51 Rectum L cell 0.7 + 
36 F 66 Rectum L cell ne ne 
37 M 39 Rectum L cell 0.3 +++ 
38 M 54 Rectum EC cell 2 ++ 
39 F 66 Rectum L cell 1.7 + 
40 M 66 Rectum L cell 1 + 
41 M 70 Rectum EC/L cell 2 +++ 
No 0 0 0 0 0 0 
No 0 0 0 0 ne 0 
No 0 0 0 0 0 0 
No 0 0 0 0 0 0 
Node 0 0 0 0 ne 0 
Node/liver 0 0 0 0 0 0 
Node/liver 0 0 0 0 ne 0 
Node/liver 20 0 0 0 ne 0 
Node 0 0 0 0 ne 0 
Node 100 0 0 ne 0 
No 0 0 0 0 0 0 
Node/liver 0 0 0 0 ne 0 
Node/liver 0 0 0 100 100 5 
Node/liver 0 0 0 40 100 80 
No 0 0 0 90 40 60 
Node 0 0 0 30 70 70 
Ne 0 0 0 100 60 70 
Node/liver 0 0 0 70 40 70 
Node 0 0 0 60 90 5 
Liver 0 0 0 100 60 80 
Node 0 0 0 i0 30 40 
No 0 0 0 90 100 30 
No 0 0 0 70 90 5 
No 0 0 0 100 10 40 
No 0 0 0 10 ne 70 
No 0 0 0 30 0 60 
No 0 0 0 100 20 60 
No 0 0 0 100 10 80 
No 0 0 0 100 0 3 
No 60 60 100 0 0 0 
Liver 0 0 0 100 ne 20 
Ne 0 0 0 30 50 5 
Omentum 0 0 0 90 0 5 
Liver 0 0 0 100 80 5 
No 0 5 0 0 0 0 
No 3 40 15 0 ne 0 
No 0 90 0 0 ne 0 
No 10 0 0 80 0 30 
No 0 0 0 0 0 0 
No 0 20 10 0 0 0 
No 0 0 40 30 0 10 
a Immunoreactivities for gastrin 34 and C-terminus gastrin-CCK-cerulein were found only in case 11 
b See "Materials and methods" 
Table 2 Antibodies and antisera used 
Antibodies/antisera Clone/code Dilution Source 
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Neuron specific enolase (NSE) A589 1:200 
Chromogranin A (CgA) Phe5 1:50 
Chromogranin B (CgB) B 11 1:4000 
Glicentin-glucagon (Glic) B 37-1 1:2500 
Pancreatic polypeptide (PP) CA08327 1:4000 
Somatostatin (Sore) A566 1:500 
Somatostatin (Som) 786 OC 1:10 
Secretin (Sect) B33-1 1:500 
Serotonin (5HT) YC5 1:50 
Substance P (Sub P) B45-1 1:640 
C-terminus gastrin-CCK-cerulein (Cer) B4 1 : 10000 
Gastrin 34 (Gastr) RA-08-090 1:500 
Acidic fibroblast growth factor (aFGF) 06-101 1:100 
Basic fibroblast growth factor (bFGF) 05-118 1:100 
Dako, Copenhagen, Denmark 
Enzo Diagnostics, New York, USA 
Dr. Siccardi, University of Milan, Italy 
Milab, Malmo, Sweden 
Cambridge Research Biochemicals, Cambridge, UK 
Dako 
Labometrics, Milan, Italy 
Milab 
Biogenesis, Bournemouth, UK 
Milab 
Farmitalia, Milan, Italy 
Cambridge 
UBI, Lake Placid, NY, USA 
UBI 
Fig. 1 a Acidic fibroblast 
growth factor (aFGF) and b se- 
rotonin immunoreactivities in 
normal human duodenal muco- 
sa. Only a subgroup of seroto- 
nin-positive cells (arrows) 
shows aFGF immunoreactivity. 
x400 
Fig. 2 a Glicentin, b aFGF and 
e serotonin immunoreactivities 
in normal human rectal muco- 
sa. Glicentin-positive c lls are 
unreactive with anti-aFGF anti- 
bodies which, in contrast, rec- 
ognize a subpopulation f sero- 
tonin-positive c lls (arrows). 
x250 
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mours). The clinico-pathological d ta for these tumours are given 
in Table 1. 
For all histological, histochemical nd immunohistochemical 
studies, tissues were fixed in buffered formalin (formaldehyde 4% 
w/v and acetate buffer 0.05 M) and routinely embedded in paraf- 
fin. Serial sections were stained with haematoxylin-eosin (H&E) 
for histological evaluation, with van Gieson stain for the evalua- 
tion of the fibrous stroma, and with Grimelius' silver impregnation 
for argyrophil cell detection. The amount of fibrous stroma was 
scored on van Gieson stained sections into three categories: (+) 
scant, when the fibrous stroma represented less than 10% of the 
neoplastic tissue; (++) intermediate, when it was from 10% to 
50%, and (+++) abundant when it was more than 50%. 
A panel of immunohistochemical st ins was performed on seri- 
al reverse face sections using the antibodies and antisera listed in 
Table 2. Sections, cut at 3 btm and mounted on slides coated with 
poly-L-lysine, were deparaffinized and hydrated through graded 
alcohol to water. The endogenous peroxidase activity was 
quenched by plunging sections in 3% hydrogen peroxide for 
10 rain. Primary antibody incubation was done at 4°C for 18-20 h, 
followed by the avidin-biotin complex (ABC) detection procedure 
according to Hsu et al. [28]. The sections were then immersed in 
0.03% 3,3'diaminobenzidine t trahydrochloride and counter- 
stained with Harris' haematoxylin. The sections tained for glicen- 
tin and somatostatin (Dako, polyclonal) were pretreated for 10 min 
with 0.003% subtilisin (Sigma, P4789; protease type XXVII or 
Nagarse protease) in 0.05 M TRIS-buffered saline pH 7.4, while 
sections stained for aFGF were pretreated with 0.01 M citrate 
buffer pH 6 (2 x 5 min) in a microwave oven at 650 W. Colocal- 
ization studies were performed using both 3 gin serial reverse face 
sections [18] and double immunostain performed according to 
Mason et al. [35] or Lan et al. [30]. Specificity controls consisted 
of absorption of each antiserum with 10-50 nM/ml of the antigen 
and related or unrelated amines or peptides, including bFGF 
(PBH, Hannover, Germany) and serotonin conjugated with bovine 
serum albumin (BSA)-pNH2-phenylalanine (Prof. R. Buffa, Uni- 
versity of Milan), and omission of the first layer, and use of con- 
trol tissues with or without he pertinent antigen. 
Fig. 3 Normal human duodenal mucosa: colocalization of seroto- 
nin (brown) and aFGF (red) in some enterochromaffin cells, aFGF 
revealed with anti-rabbit mmunoglobulins conjugated to alkaline 
phosphatase, followed by enzyme development with FastRed as 
chromogen, x630 
Results 
aFGF was detected by immunohistochemica l  analysis in 
scattered endocrine cells present in the mucosa of  the 
whole gastrointestinal tract. The immunohistochemica l  
staining was clearly granular and diffuse in the cyto- 
plasm. The staining was prevented by absorption with 
10 nM aFGF, but not by absorption with 20 nM bFGF or 
50 nM serotonin. Gastric mucosa showed rather scanty 
aFGF- immunoreact ive  (IR) cells, which were part icular- 
ly rare in the fundus. In contrast, aFGF- IR  cells were nu- 
merous in the mucosa of duodenum, je junum and i leum, 
as wel l  as in that of  the right colon and rectum. In adja- 
cent 3 -gm sections aFGF- IR  cells stained strongly with 
serotonin antibodies (Fig. 1), whi le fai l ing to react with 
antisera or antibodies directed against C-terminus gas- 
tr in-CCK-cerulein,  somatostatin, gl icentin (Fig. 2) and 
secretin. Double label l ing studies conf i rmed that all 
aFGF- IR  cells were serotonin posit ive (Fig. 3) and 
proved that a fraction (about 1/3) of serotonin- IR cells 
fai led to stain with aFGF antibody. Double immuno-  
stains conf i rmed that aFGF was not contained in somato- 
statin- (Fig. 4), gastr in-CCK-cerulein- ,  gl icentin- and se- 
cret in- immunoreact ive c lls. No substance P-posit ive 
cells were found in the normal  gastrointestinal mucosa. 
Sections of normal  gastrointestinal mucosae from sev- 
en subjects expressed few bFGF reactive endocrine cells, 
Fig. 4 Normal human duodenal mucosa: different localization of 
somatostatin (brown) and aFGF (red) in endocrine cells, aFGF re- 
vealed with anti-rabbit mmunoglobulins conjugated to alkaline 
phosphatase, followed by enzyme development with FastRed as 
chromogen, x400 
Fig. 5 a aFGF and b serotonin 
immunoreactivities in an ileal 
endocrine turnout, x200 
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which were more numerous in the gastric antral mucosa 
and were very few in the small intestinal mucosa. 
In 23 of the 41 gastrointestinal endocrine tumours ex- 
amined, immunostaining for aFGF showed significant 
numbers of positively staining cells and was restricted to 
cases with serotonin-positive c lls (Fig. 5). Most (81%) 
of the aFGF- and serotonin-IR cells were also substance 
P positive. The percentage of aFGF positive cells, varied 
from tumour to turnout, ranging from 5% to 100%, with 
a mean of 40%. The mean percentage of serotonin-IR 
cells, in the same neoplams, was 75% (ranging from 
10% to 100%), indicating that, as in the normal gastroin- 
testinal mucosa, aFGF is expressed only in a subpopula- 
tion of serotonin cells. In turnouts coexpressing aFGF 
and substance P the mean percentage of aFGF-IR cells 
was 42%, while that of substance P-IR cells was 50.8% 
(ranging from 10% to 100%). None of the tumours ex- 
amined, including ECL cell gastric carcinoids, showed 
positive staining for bFGF. 
The amount of fibrous stroma was comparatively 
evaluated in 22 serotonin- and aFGF-positive EC cell tu- 
rnouts and in 15 serotonin- and aFGF-negative tumours 
(Table 3). The former group was associated with abun- 
dant or intermediate fibrous stroma in 21of 22 cases 
(95.5%), while only 1 (4.5%) case had scanty stroma. In 
contrast, of the 15 serotonin- and aFGF-negative tu- 
mours, only 2 (13.3%) showed abundant fibrous stroma, 
and only 3 (20%) presented an intermediate fibrous stro- 
ma. The majority of these neoplasms (10/15, 66.7%) had 
scanty fibrous stromal reaction. 
No relationships were found between expression of 
aFGF and malignancy of the turnout, the marker being 
about equally expressed in benign appendiceal tumours 
and in malignant ileal and colonic endocrine neoplasms 
(see Table 1). 
Table 3 Relationship between amount of fibrous stroma nd sero- 
tonin and aFGF expression i  gut endocrine turnouts. (figures in 
round brackets are percentages) 
Fibrous stroma 






turnouts 1 (4.5) 12 (54.5) 9 (41) 
turnouts 10 (66.7) 3 (20) 2 (13.3) 
We have shown that antibodies against aFGF identify a 
population of endocrine cells scattered in the normal gas- 
trointestinal mucosa as well as in turnouts composed of 
EC cells, which are known to produce serotonin and 
tachykinins. The aFGF-IR cells represent a fraction of 
serotonin-IR cells of the normal gut, while they are not 
related to other functional types of endocrine cells, such 
as gastrin (G), CCK, secretin (S), somatostatin (D) and 
glicentin (L) cells. 
aFGF immunoreactivity was also expressed in seroto- 
nin- and substance P-producing (EC) cell tumours (ar- 
gentaffin carcinoids), but not in other functional types of 
endocrine turnouts of the gut investigated, including gas- 
tric ECL cell, duodenal somatostatin and gastrin cell tu- 
mours, and rectal L cell tumours. These findings indicate 
that aFGF may be considered to be a specific marker for 
EC cell tumours and that it should be used in addition to 
serotonin and tachykinins (substance R neurokinin A and 
B and neuropeptide K) to characterize these lesions. 
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In addition, our results demonstrate hat, at least in 
our experimental conditions, the distribution of aFGF in 
endocrine cells of the gut and related tumours, appears to 
be different from that of bFGE The bFGF-IR cells were 
most numerous in the normal gastric mucosa where only 
few aFGF-IR cells were found, and in contrast aFGF-IR 
cells were numerous in the small intestine, where bFGF- 
IR cells were absent or very few. The absence of bFGF 
reactivity that we found in EC-cell turnouts hould indi- 
cate that this growth factor, unlike aFGF, cannot be re- 
garded as a tumour marker. However, our findings con- 
trast with those of Alhman et al. [1], which showed a 
strong immunopositive r action with bFGF antiserum in 
tumour cells of 30 neuroendocrine tumours of the diges- 
tive system. These different results may be due to the 
different conditions of tissue processing and use of dif- 
-ferent anti-bFGF antibodies. In this context, in the paper 
of Ahlman et al. [1] there is no mention of the specificity 
tests proving that the bFGF antibodies employed were 
not cross-reactive with aFGF. Technical problems may 
also explain the lack of bFGF-IR that we found in gastric 
ECL cell tumours, which contrasts with the positivity 
shown by Bordi et al. [7] in the same type of tumours. 
It is well known that intestinal EC cell tumours (ar- 
gentaffin carcinoids) are associated with significant stro- 
mal fibrosis when there is invasion of the muscular layer, 
which may be combined with peritoneal adhesions and 
intestinal obstruction. Moreover, a "carcinoid heart dis- 
ease" characterized bylarge fibrous plaques on the endo- 
cardial surface of cardiac chambers and of valvular 
cusps, mainly of the right side, may be associated with 
the carcinoid syndrome. Although serotonin and other 
vasoactive substances have been implicated as responsi- 
ble for the fibrosis, the relationship between these sub- 
stances and desmoplastic reaction has not been well de- 
fined. Experimental data have shown that serotonin alone 
does not have a mitogenic effect on Chinese hamster 
lung fibroblasts, but it can potentiate he mitogenic effect 
caused by bFGF [46]. Some authors [1, 5, 12, 13, 41, 42] 
have shown that midgut endocrine tumours produce sev- 
eral growth factors, including PDGF, TGFo~, TGF[31, 
TGF~2, TGF~3, insulin like growth factor-I and bFGF, 
that may interfere with mechanisms regulating stromal 
reaction, angiogenesis and tumour growth. 
Our results have shown a correlation between aFGF 
expression and the amount of fibrous stroma present in 
the gut endocrine tumours (Table 3), suggesting that 
aFGF might be involved in proliferation and activity of 
stromal fibroblasts. Other trophic responses to the pro- 
duction and local release of aFGF by EC cell tumours, 
(not examined in the present study) may include prolifer- 
ation of smooth muscle tissue within the tumour stroma 
or peritumour gut wall [8, 37] and elastic sclerosis of 
medium size mesenteric arteries and veins [2, 43]. The 
proliferation of smooth muscle cells within the tumours 
and in the extratumoural muscularis mucosae of stom- 
achs harbouring astric ECL cell carcinoids has been 
well documented by Bordi et al. [8]. In gastric tumours, 
the proliferative response of smooth muscle cells has 
been supposed to be induced by bFGF. Since aFGF is 
known to be a potent mitogen for smooth muscle cells 
[t0], like bFGF, the hypertrophy of the muscularis pro- 
pria underlying the carcinoid tumours of the small intes- 
tine [37] and contributing to the mechanism of small 
bowel obstruction might be induced by this growth fac- 
tor. Our preliminary unpublished observations (A.M. 
Chiaravalli, S. La Rosa, C. Capella, 1996) showing the 
presence of a significant component of c~-smooth muscle 
actin immunoreactive cells within the stroma of 10 out of 
13 aFGF-positive EC cell tumours, as against 3 out of 11 
aFGF-negative non EC cell gastrointestinal endocrine tu- 
mours, further support he hypothesis of an involvment 
of aFGF in smooth muscle proliferation. 
A possible role of aFGF in the pathogenesis of char- 
acteristic obliterative lastic sclerosis of peritumour and 
mesenteric blood vessels associated with EC cell car- 
cinoids [2, 43] appears questionable, since the effect of 
aFGF on the production of elastic fibers is not known 
and experimental studies have shown that aFGF pro- 
motes vascular epair and inhibits intimal thickening in 
response to intravascular damage [6]. 
The possible functional role of aFGF produced by tu- 
mour cells in the proliferation of stromal fibroblasts and 
smooth muscle cells has to be substantiated by the dem- 
onstration of aFGF receptors in the target mesenchymal 
cells. In this context, it is interesting to recall that aFGF 
is synthesized as a cytosolic protein without a signal se- 
quence, but it can be exported from Cells by an unknown 
mechanism [15]. The biological activity of aFGF is me- 
diated by high affinity transmembrane receptors consist- 
ing of an intracellular tyrosine kinase domain and an ex- 
tracellular binding domain with immunoglobulin loop- 
like motifs [24]. The role of aFGF relative to other fibro- 
blast stimulating factors, such as IGF-I, PDGF, TGFo~, 
TGF[3, and their possible interactions remain to be estab- 
lished. 
In addition to or as an alternative toparacrine stimula- 
tion of tumour stromal cells as an explanation, a possible 
regulatory effect of aFGF on normal and neoplastic EC 
cell function might be suggested. Although no data are 
available on the effect of aFGF on EC cells, other cellu- 
lar models indicate that aFGF may be an autocrine cell 
regulator. In this context, it is interesting to recall that 
aFGF is an intrinsic component of retinal photoreceptor 
cells, where it has been localized by both immunocyto- 
chemical and in situ hybridization techniques [34]. In ad- 
dition, rod outer segments contain specific receptors for 
aFGF, as has been demonstrated by Mascarelli et al. 
[34]. aFGF has also been shown to enhance rhodopsin 
synthesis in newborn rat photoreceptor cells in vitro. All 
these findings seem to indicate that aFGF may have an 
important role in photoreceptor physiology. A similar 
regulating role seems to be exerted by aFGF on pancreat- 
ic acini, where is known to stimulate amylase release 
[11]. 
Recent immunohistochemical studies have demon- 
strated much more intense xpression of aFGF in malig- 
nant tumours than in normal tissues. Elevated intracellu- 
lar aFGF immunoreactivity has been reported in brain tu- 
mours [36, 47]. In carcinomas, aFGF is overexpressed in 
pancreatic carcinoma [50], oral carcinoma [39], and sali- 
vary gland carcinoma [40]. In certain types of malignan- 
cies the overexpression f aFGF seems to correlate with 
advanced tumour stages [50]. At variance with these 
findings, aFGF immunoreactivity of  EC cell tumours is 
not related to malignancy, being present both in benign 
appendiceal tumours, and in malignant ileal and colonic 
tumours, It is not overexpressed in neoplastic EC cells 
relative to normal EC cells. 
In conclusion, our results show that aFGF is ex- 
pressed in a fraction of  normal gastrointestinal serotonin 
producing EC cells; is constantly expressed by gut sero- 
tonin-producing endocrine tumours and should therefore 
be considered a marker for gut EC cell tumours (argen- 
taffin carcinoids), being useful for differentiation of 
these turnouts from other functional types of  gastrointes- 
tinal endocrine tumours; and may be involved, in con- 
juction with other growth factor peptides, in the stromal 
fibroblast reaction frequently found in these endocrine 
neoplasms. 
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